A Novel LC-MS/MS Assay for Quantifying Dermatan Sulfate as a Cerebrospinal Fluid Biomarker for Mucopolysaccharidosis II Disease

Accumulation of dermatan sulfate (DS) in tissue and body fluid leads to mucopolysaccharidosis II (MPS II) disorder. The study aims to develop an LC-MS/MS assay to measure DS in human cerebrospinal fluid (CSF) as a biomarker.

"*" indicates required fields

First Name*

Last Name*

Company*

State*

Country

Email*

Phone*

Please only hit the submit button once.

I AGREE*

By submitting this form I agree that Frontage may process my data in the manner described in Frontage’s Privacy Policy.

Comments

This field is for validation purposes and should be left unchanged.

A Novel LC-MS/MS Assay for Quantifying Dermatan Sulfate as a Cerebrospinal Fluid Biomarker for Mucopolysaccharidosis II Disease

Resources to Consider

Development and validation of an LC-MS/MS method for the...

Development and Validation of an Ultra Sensitive LC-MS/MS Method for...

Development And Validation Of LC-MS/MS Methods For The…

Simultaneous Determination of Coproporphyrin-I and Coproporphyrin-III...

Validation of a Low-Volume Plasma LC-MS/MS Method Using a...

Overcoming Stability Issues in the Development of an LC-MS/MS...

Bioanalysis of Liposome Drugs by LC-MS/MS

Sequencing Assays for Biomarker Discovery and Pharmacodynamics in...

Qualification of the Quanterix Phospho-Tau 217 (pTau-217) assay using...

A Competitive Ligand-binding Assay for the Detection of Neutralizing...

Immunoassays for Drug Discovery

Testing of Carryover & After MRD Benchtop Stability for...